Relation between the vasodilator-stimulated phosphoprotein phosphorylation assay and light transmittance aggregometry in East Asian patients after high-dose clopidogrel loading

American Heart Journal

Volumn 166, Issue 1, 2013, Pages 95-103

  Kim, In Suk ^a   Jeong, Young Hoon ^b,c   Tantry, Udaya S ^b   Park, Yongwhi ^c   Lee, Dong Hyun ^d   Bliden, Kevin P ^b   Koh, Jin Sin ^c   Park, Jeong Rang ^c   Jang, Jae Sik ^e   Hwang, Seok Jae ^c   Koh, Eun Ha ^d   Kwak, Choong Hwan ^c   Hwang, Jin Yong ^c   Kim, Sunjoo ^d   Gurbel, Paul A ^b  

^a Pusan National University School of Medicine   (South Korea)

^b SINAI CENTER FOR THROMBOSIS RESEARCH   (United States)

^c Gyeongsang National University School of Medicine   (South Korea)

^d Gyeongsang National University   (South Korea)

^e Inje University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE; CLOPIDOGREL; VASODILATOR STIMULATED PHOSPHOPROTEIN;

ADULT; ANALYTIC METHOD; ARTICLE; ASIAN; DRUG MEGADOSE; FEMALE; HUMAN; LIGHT TRANSMITTANCE AGGREGOMETRY; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PLATELET REACTIVITY; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN PHOSPHORYLATION; SMOKING; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION;

BLOOD PLATELETS; CELL ADHESION MOLECULES; CORONARY ARTERY DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MICROFILAMENT PROTEINS; MIDDLE AGED; PHOSPHOPROTEINS; PHOSPHORYLATION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PROSPECTIVE STUDIES; TICLOPIDINE;

EID: 84879785689     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2013.03.030     Document Type: Article

References (37)

1. P.A. Gurbel, R.C. Becker, and K.G. Mann Platelet function monitoring in patients with coronary artery disease J Am Coll Cardiol 50 2007 1822 1834
2. L. Bonello, U.S. Tantry, and R. Marcucci Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate J Am Coll Cardiol 56 2010 919 933
3. P.A. Gurbel, and U.S. Tantry Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents?: platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents Circulation 125 2012 1276 1287
4. N.J. Breet, J.W. van Werkum, and H.J. Bouman Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation JAMA 303 2010 754 762
5. G. Parodi, R. Marcucci, and R. Valenti High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI JAMA 306 2011 1215 1223
6. Y.H. Jeong, I.S. Kim, and B.R. Choi The optimal threshold of high post-treatment platelet reactivity could be defined by a point-of-care VerifyNow P2Y12 assay Eur Heart J 29 2008 2186 2187
7. I.S. Kim, Y.H. Jeong, and M.K. Kang Correlation of high post-treatment platelet reactivity assessed by light transmittance aggregometry and the VerifyNow P2Y12 assay J Thromb Thrombolysis 30 2010 486 495
8. Y. Park, Y.H. Jeong, and I.S. Kim The concordance and correlation of measurements by multiple electrode and light transmittance aggregometries based on the pre-defined cutoffs of high and low on-treatment platelet reactivity Platelets 23 2012 290 298
9. V. Krishna, G.A. Diamond, and S. Kaul Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents?: the role of platelet reactivity and genotype testing in the prevention of atherothrombotic cardiovascular events remains unproven Circulation 125 2012 1288 1303
10. D. Sibbing, R.A. Byrne, and I. Bernlochner High platelet reactivity and clinical outcome - fact and fiction Thromb Haemost 106 2011 191 202
11. D. Aradi, A. Komócsi, and A. Vorobcsuk Prognostic significance of high on-clopidogrel platelet reactivity after percutaneous coronary intervention: systematic review and meta-analysis Am Heart J 160 2010 543 551
12. U.R. Schwarz, J. Geiger, and U. Walter Flow cytometry analysis of intracellular VASP phosphorylation for the assessment of activating and inhibitory signal transduction pathways in human platelets - definition and detection of ticlopidine/clopidogrel effects Thromb Haemost 82 1999 1145 1152
13. B. Aleil, C. Ravanat, and J.P. Cazenave Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases J Thromb Haemost 3 2005 85 92
14. H.M. Judge, R.J. Buckland, and A. Sugidachi Relationship between degree of P2Y12 receptor blockade and inhibition of P2Y12-mediated platelet function Thromb Haemost 103 2010 1210 1217
15. C. Sollier, N. Berge, and B. Boval Differential sensitivity and kinetics of response of different ex vivo tests monitoring functional variability of platelet response to clopidogrel Thromb Haemost 104 2010 571 581
16. D. Aradi, T. Magyarlaki, and M. Tokés-Füzesi Comparison of conventional aggregometry with VASP for monitoring P2Y12-specific platelet inhibition Platelets 21 2010 563 570
17. A. Schäfer, S. Weinberger, and U. Flierl ADP-induced platelet aggregation frequently fails to detect impaired clopidogrel-responsiveness in patients with coronary artery disease compared to a P2Y12-specific assay Thromb Haemost 100 2008 618 625
18. P.A. Gurbel, K.P. Bliden, and K.M. Hayes The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting J Am Coll Cardiol 45 2005 1392 1396
19. Y.G. Ko, J.W. Suh, and B.H. Kim Comparison of 2 point-of-care platelet function tests, VerifyNow Assay and Multiple Electrode Platelet Aggregometry, for predicting early clinical outcomes in patients undergoing percutaneous coronary intervention Am Heart J 161 2011 383 390
20. M.K. Kang, Y.H. Jeong, and S.E. Yoon Pre-procedural platelet reactivity after clopidogrel loading in Korean patients undergoing scheduled percutaneous coronary intervention J Atheroscler Thromb 17 2010 1122 1131
21. J.H. Jung, P.K. Min, and S.H. Lee Clopidogrel pretreatment before primary percutaneous coronary stenting in patients with acute ST-segment elevation myocardial infarction: comparison of high loading dose (600 mg) versus low loading dose (300 mg) Coron Artery Dis 20 2009 150 154
22. Y.B. Song, J.Y. Hahn, and H.C. Gwon A high loading dose of clopidogrel reduces myocardial infarct size in patients undergoing primary percutaneous coronary intervention: a magnetic resonance imaging study Am Heart J 163 2012 500 507
23. Choi CU, Rha SW, Oh DJ, et al. Standard versus high loading doses of clopidogrel in Asian ST-segment elevation myocardial infarction patients undergoing percutaneous coronary intervention: insights from the Korea Acute Myocardial Infarction Registry. Am Heart J 2011;161:373-82.e1-3.
24. P.A. Gurbel, M.J. Antonino, and K.P. Bliden Platelet reactivity to adenosine diphosphate and long-term ischemic event occurrence following percutaneous coronary intervention: a potential antiplatelet therapeutic target Platelets 19 2008 595 604
25. Y.H. Jeong, K.P. Bliden, and U.S. Tantry High on-treatment platelet reactivity assessed by various platelet function tests: is the consensus-defined cut-off of VASP-P platelet reactivity index too low? J Thromb Haemost 10 2012 487 489
26. 12 receptors in platelets and other hematopoietic and non-hematopoietic cells Purinergic Signal 8 2012 609 619
27. A. Schfer, U. Flierl, and J. Kossler Early determination of clopidogrel responsiveness by platelet reactivity index identifies patients at risk for cardiovascular events after myocardial infarction Thromb Haemost 106 2011 141 148
28. S. El Ghannudi, P. Ohlmann, and N. Meyer Impact of P2Y12 inhibition by clopidogrel on cardiovascular mortality in unselected patients treated by percutaneous coronary angioplasty: a prospective registry JACC Cardiovasc Interv 3 2010 648 656
29. M.K. Freynhofer, I. Brozovic, and V. Bruno Multiple electrode aggregometry and vasodilator stimulated phosphoprotein-phosphorylation assay in clinical routine for prediction of postprocedural major adverse cardiovascular events Thromb Haemost 106 2011 230 239
30. H.S. Kim Adjunctive cilostazol versus double dose clopidogrel after PCI with drug eluting stent: the HOST-ASSURE randomized trial Presented at American College of Cardiology Meeting 2012 at Chicago, USA 2012
31. T. Kimura, T. Morimoto, and Y. Nakagawa Antiplatelet therapy and stent thrombosis after sirolimus-eluting stent implantation Circulation 119 2009 987 995
32. P.A. Gurbel, U.S. Tantry, and K.P. Bliden Immunity to thrombotic events is achievable if we stop the guessing game: is this the major hidden message from GRAVITAS? Thromb Haemost 106 2011 263 264
33. M. Man, M. Farmen, and C. Dumaual Genetic variation in metabolizing enzyme and transporter genes: comprehensive assessment in 3 major East Asian subpopulations with comparison to Caucasians and Africans J Clin Pharmacol 50 2010 929 940
34. Y.H. Jeong Accelerated inhibition of platelet aggregation, inflammation, myonecrosis by adjunctive cilostazol loading in patients with acute coronary syndrome: the results of the ACCEL-LOADING-ACS multicenter randomized trial Presented at American College of Cardiology Meeting 2012 at Chicago, USA J Am Coll Cardiol 59 (13) 2012 E455
35. S.G. Ahn, S.H. Lee, and J.H. Yoon Different prognostic significance of high on-treatment platelet reactivity as assessed by the VerifyNow P2Y12 Assay after coronary stenting in patients with and without acute myocardial infarction JACC Cardiovasc Interv 5 2012 259 267
36. N.A. Zakai, and L.A. McClure Racial differences in venous thromboembolism J Thromb Haemost 9 2011 1877 1882
37. A. Kelley-Hedgepeth, D.M. Lloyd-Jones, and A. Colvin SWAN Investigators. Ethnic differences in C-reactive protein concentrations Clin Chem 54 2008 1027 1037